NMOSD
AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
May 30, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris
AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …
AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD
May 11, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology
AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …
Roche’s satralizumab succeeds in second positive study in rare CNS disease
September 12, 2019Research and Development NMOSD, Roche, satralizumab
In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …
Latest content
